147 related articles for article (PubMed ID: 23208052)
41. Effect of zymosan and poly (I:C) adjuvants on responses to microneedle immunization coated with whole inactivated influenza vaccine.
Shin JH; Noh JY; Kim KH; Park JK; Lee JH; Jeong SD; Jung DY; Song CS; Kim YC
J Control Release; 2017 Nov; 265():83-92. PubMed ID: 28890214
[TBL] [Abstract][Full Text] [Related]
42. Mass vaccination: solutions in the skin.
Glenn GM; Kenney RT
Curr Top Microbiol Immunol; 2006; 304():247-68. PubMed ID: 16989274
[TBL] [Abstract][Full Text] [Related]
43. Progress in microneedle array patch (MAP) for vaccine delivery.
Nguyen TT; Oh Y; Kim Y; Shin Y; Baek SK; Park JH
Hum Vaccin Immunother; 2021 Jan; 17(1):316-327. PubMed ID: 32667239
[TBL] [Abstract][Full Text] [Related]
44. Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin.
Prausnitz MR
Annu Rev Chem Biomol Eng; 2017 Jun; 8():177-200. PubMed ID: 28375775
[TBL] [Abstract][Full Text] [Related]
45. Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development.
Adhikari BB; Goodson JL; Chu SY; Rota PA; Meltzer MI
Drugs R D; 2016 Dec; 16(4):327-338. PubMed ID: 27696306
[TBL] [Abstract][Full Text] [Related]
46. Transdermal delivery of relatively high molecular weight drugs using novel self-dissolving microneedle arrays fabricated from hyaluronic acid and their characteristics and safety after application to the skin.
Liu S; Jin MN; Quan YS; Kamiyama F; Kusamori K; Katsumi H; Sakane T; Yamamoto A
Eur J Pharm Biopharm; 2014 Feb; 86(2):267-76. PubMed ID: 24120887
[TBL] [Abstract][Full Text] [Related]
47. Microneedle Systems for Vaccine Delivery: the story so far.
Hossain MK; Ahmed T; Bhusal P; Subedi RK; Salahshoori I; Soltani M; Hassanzadeganroudsari M
Expert Rev Vaccines; 2020 Dec; 19(12):1153-1166. PubMed ID: 33427523
[TBL] [Abstract][Full Text] [Related]
48. Fabrication, Physicochemical Characterization, and Performance Evaluation of Biodegradable Polymeric Microneedle Patch System for Enhanced Transcutaneous Flux of High Molecular Weight Therapeutics.
Shah V; Choudhury BK
AAPS PharmSciTech; 2017 Nov; 18(8):2936-2948. PubMed ID: 28432615
[TBL] [Abstract][Full Text] [Related]
49. Recent insights into cutaneous immunization: How to vaccinate via the skin.
Engelke L; Winter G; Hook S; Engert J
Vaccine; 2015 Sep; 33(37):4663-74. PubMed ID: 26006087
[TBL] [Abstract][Full Text] [Related]
50. Microneedles: A smart approach and increasing potential for transdermal drug delivery system.
Waghule T; Singhvi G; Dubey SK; Pandey MM; Gupta G; Singh M; Dua K
Biomed Pharmacother; 2019 Jan; 109():1249-1258. PubMed ID: 30551375
[TBL] [Abstract][Full Text] [Related]
51. Performance and characteristics evaluation of a sodium hyaluronate-based microneedle patch for a transcutaneous drug delivery system.
Hiraishi Y; Nakagawa T; Quan YS; Kamiyama F; Hirobe S; Okada N; Nakagawa S
Int J Pharm; 2013 Jan; 441(1-2):570-9. PubMed ID: 23137695
[TBL] [Abstract][Full Text] [Related]
52. A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza.
Andersen TK; Zhou F; Cox R; Bogen B; Grødeland G
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931687
[TBL] [Abstract][Full Text] [Related]
53. Microneedle arrays delivery of the conventional vaccines based on nonvirulent viruses.
Li N; Wang N; Wang X; Zhen Y; Wang T
Drug Deliv; 2016 Nov; 23(9):3234-3247. PubMed ID: 26967666
[TBL] [Abstract][Full Text] [Related]
54. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery.
Babiuk S; Baca-Estrada M; Babiuk LA; Ewen C; Foldvari M
J Control Release; 2000 May; 66(2-3):199-214. PubMed ID: 10742580
[TBL] [Abstract][Full Text] [Related]
55. Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(+) T cell responses.
Fernando GJ; Zhang J; Ng HI; Haigh OL; Yukiko SR; Kendall MA
J Control Release; 2016 Sep; 237():35-41. PubMed ID: 27381247
[TBL] [Abstract][Full Text] [Related]
56. Design and characterisation of a dissolving microneedle patch for intradermal vaccination with heat-inactivated bacteria: A proof of concept study.
Rodgers AM; McCrudden MTC; Vincente-Perez EM; Dubois AV; Ingram RJ; Larrañeta E; Kissenpfennig A; Donnelly RF
Int J Pharm; 2018 Oct; 549(1-2):87-95. PubMed ID: 30048778
[TBL] [Abstract][Full Text] [Related]
57. Transcutaneous immunization with Intercell's vaccine delivery system.
Seid RC; Look JL; Ruiz C; Frolov V; Flyer D; Schafer J; Ellingsworth L
Vaccine; 2012 Jun; 30(29):4349-54. PubMed ID: 22682290
[TBL] [Abstract][Full Text] [Related]
58. New vaccination technologies that make needles redundant.
Senior K
Lancet Infect Dis; 2011 Jan; 11(1):16-7. PubMed ID: 21226239
[No Abstract] [Full Text] [Related]
59. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies.
Karande P; Mitragotri S
Annu Rev Chem Biomol Eng; 2010; 1():175-201. PubMed ID: 22432578
[TBL] [Abstract][Full Text] [Related]
60. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
Fernando GJP; Hickling J; Jayashi Flores CM; Griffin P; Anderson CD; Skinner SR; Davies C; Witham K; Pryor M; Bodle J; Rockman S; Frazer IH; Forster AH
Vaccine; 2018 Jun; 36(26):3779-3788. PubMed ID: 29779922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
